Health Care • Biotechnology: Pharmaceutical Preparations
$33.48 ▼ -0.27
(-0.80%)
MKT CAP: $1.64B • VOL: 1.44M
52W L $17 52W H $51
URGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $109.8M | $90.4M | $82.7M |
| YoY Revenue Growth % | +21.4% | +9.3% | — |
| Gross Profit | $97.3M | $81.5M | — |
| Gross Margin % | 88.7% | 90.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$124.9M | -$96.8M | -$65.5M |
| Operating Margin % | -80.0% | -80.0% | -79.2% |
| Net Income (GAAP) | -$153.5M | -$126.9M | -$102.2M |
| EBITDA (Normalized) | -$124.6M | -$96.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$162.4M | -$96.8M | -$76.4M |
| Capital Expenditures (CapEx) | $289.0K | $295.0K | — |
| Free Cash Flow (FCF) | -$162.7M | -$97.1M | -$76.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $110.7M | $172.0M | — |
| Total Debt (Short + Long Term) | $122.2M | $121.7M | — |
| Total Stockholders' Equity | -$105.5M | -$8.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR URGN.